

Pranatharthi H Chandrasekar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7551305/publications.pdf>

Version: 2024-02-01

63
papers

8,448
citations

257101

24
h-index

138251

58
g-index

63
all docs

63
docs citations

63
times ranked

5008
citing authors

#	ARTICLE	IF	CITATIONS
1	Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis. New England Journal of Medicine, 2002, 347, 408-415.	13.9	3,048
2	Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease. New England Journal of Medicine, 2007, 356, 335-347.	13.9	1,228
3	A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation. New England Journal of Medicine, 1992, 326, 845-851.	13.9	1,175
4	Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial. Clinical Infectious Diseases, 2007, 44, 2-12.	2.9	724
5	Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial. Annals of Internal Medicine, 2003, 138, 705.	2.0	351
6	A Double-blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients. Clinical Infectious Diseases, 2002, 35, 359-366.	2.9	308
7	Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease. Pharmacotherapy, 2007, 27, 1627-1636.	1.2	163
8	Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD)., 1999, 61, 194-202.		126
9	Adverse effects of voriconazole: Over a decade of use. Clinical Transplantation, 2016, 30, 1377-1386.	0.8	96
10	Bone and Joint Infections in Intravenous Drug Abusers. Clinical Infectious Diseases, 1986, 8, 904-911.	2.9	84
11	Drug-Induced Nephrotoxicity Caused by Amphotericin B Lipid Complex and Liposomal Amphotericin B. Medicine (United States), 2010, 89, 236-244.	0.4	81
12	Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin*. Clinical Pharmacology and Therapeutics, 1995, 58, 617-624.	2.3	78
13	Management of invasive fungal infections: a role for polyenes. Journal of Antimicrobial Chemotherapy, 2011, 66, 457-465.	1.3	76
14	<i>Clostridium difficile</i> infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Review of Anti-Infective Therapy, 2010, 8, 1113-1119.	2.0	75
15	Amphotericin B Lipid Complex in the Management of Invasive Aspergillosis in Immunocompromised Patients. Clinical Infectious Diseases, 2005, 40, S392-S400.	2.9	66
16	Candida auris: a worrisome, globally emerging pathogen. Expert Review of Anti-Infective Therapy, 2017, 15, 819-827.	2.0	64
17	The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Journal of Antimicrobial Chemotherapy, 1994, 33, 309-318.	1.3	63
18	Clostridium Difficile Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic Strains. Biology of Blood and Marrow Transplantation, 2016, 22, 157-163.	2.0	59

#	ARTICLE	IF	CITATIONS
19	Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. <i>Infection and Drug Resistance</i> , 2016, Volume 9, 291-300.	1.1	52
20	Diagnostic challenges and recent advances in the early management of invasive fungal infections. <i>European Journal of Haematology</i> , 2010, 84, 281-290.	1.1	43
21	Infectious Diseases Subspecialty: Declining Demand Challenges and Opportunities. <i>Clinical Infectious Diseases</i> , 2014, 59, 1593-1598.	2.9	41
22	A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of <i>Aspergillus fumigatus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 914-920.	1.3	40
23	Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 2365-2374.	2.9	36
24	Management of gram-positive bacterial infections in patients with cancer. <i>Leukemia and Lymphoma</i> , 2012, 53, 8-18.	0.6	34
25	SARS-CoV-2 infection: Initial viral load (iVL) predicts severity of illness/outcome, and declining trend of iVL in hospitalized patients corresponds with slowing of the pandemic. <i>PLoS ONE</i> , 2021, 16, e0255981.	1.1	29
26	Invasive mold infections: recent advances in management approaches. <i>Leukemia and Lymphoma</i> , 2009, 50, 703-715.	0.6	28
27	Isavuconazole for Treatment of Experimental Fungal Endophthalmitis Caused by <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	23
28	Foscarnet Therapy for Acyclovir-Resistant Herpes Simplex Virus 1 Infection in Allogeneic Bone Marrow Transplant Recipients. <i>Clinical Infectious Diseases</i> , 1995, 21, 1514-1515.	2.9	21
29	Do <i>Aspergillus</i> species produce biofilm?. <i>Future Microbiology</i> , 2008, 3, 19-21.	1.0	21
30	Pathobiology of <i>Aspergillus Fumigatus</i> Endophthalmitis in Immunocompetent and Immunocompromised Mice. <i>Microorganisms</i> , 2019, 7, 297.	1.6	21
31	Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients. <i>Infection and Drug Resistance</i> , 2012, 5, 9.	1.1	19
32	Current and Future Therapeutic Options in the Management of Invasive Aspergillosis. <i>Drugs</i> , 2008, 68, 265-282.	4.9	16
33	Infectious Complications After Umbilical Cord Blood Transplantation for Hematological Malignancy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz037.	0.4	15
34	Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 36.	1.5	15
35	Bad News to Worse News: 2015 Infectious Diseases Fellowship Match Results. <i>Clinical Infectious Diseases</i> , 2015, 60, 1438.	2.9	12
36	Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2017, 25, 2593-2601.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Pneumocystis cariniiPneumonia in patients with solid tumors without acquired immune deficiency syndrome. Cancer, 1991, 68, 193-194.	2.0	9
38	Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate. Therapeutics and Clinical Risk Management, 2008, Volume 4, 1285-1294.	0.9	9
39	Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia. Mycoses, 2018, 61, 331-336.	1.8	8
40	Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine. Open Forum Infectious Diseases, 2020, 7, ofaa274.	0.4	8
41	Selection criteria for antifungals: the right patients and the right reasons. International Journal of Antimicrobial Agents, 2006, 27, 17-20.	1.1	7
42	Prophylaxis against <i>Aspergillus</i> is not perfect: problems and perils in stem cell transplantation. Medical Mycology, 2009, 47, S349-S354.	0.3	6
43	Treatment of breakthrough fungal infections: Is there one best drug strategy?. Current Fungal Infection Reports, 2009, 3, 229-235.	0.9	5
44	Evaluation of Susceptibility and Innate Immune Response in C57BL/6 and BALB/c Mice During Candida albicans Endophthalmitis. , 2020, 61, 31.		5
45	Favorable outcome of COVID-19 among African American (AA) renal transplant recipients in Detroit. Clinical Transplantation, 2021, 35, e14169.	0.8	5
46	Azole resistance in Aspergillus species: promising therapeutic options. Expert Opinion on Pharmacotherapy, 2021, 22, 1-8.	0.9	5
47	Riches usher dilemmas: Antifungal therapy in invasive aspergillosis. Biology of Blood and Marrow Transplantation, 2005, 11, 77-84.	2.0	4
48	Antifungal Therapy Strategies in Hematopoietic Stem-Cell Transplant Recipients: Early Treatment Options for Improving Outcomes. Transplantation, 2008, 86, 183-191.	0.5	4
49	Invasive aspergillosis in patients following umbilical cord blood transplant. Bone Marrow Transplantation, 2019, 54, 308-311.	1.3	4
50	Carbapenem-Susceptible Klebsiella pneumoniae and Escherichia coli Isolates Carrying a Truncated KPC Carbapenemase: a Challenge for Rapid Molecular Diagnostics. Journal of Clinical Microbiology, 2020, 58, .	1.8	4
51	Hemophagocytic lymphohistiocytosis (HLH): Elusive diagnosis of disseminated Mycobacterium avium complex infection. Germs, 2017, 7, 149-152.	0.5	4
52	Efficacy and safety of Isavuconazole for the treatment of invasive Aspergillus infection - an update of the literature. Expert Opinion on Pharmacotherapy, 2022, , 1-7.	0.9	4
53	The experience is CLEAR®. International Journal of Antimicrobial Agents, 2006, 27, 31-35.	1.1	3
54	Antifungal drugs: predicting clinical efficacy with pharmacodynamics. Expert Review of Clinical Pharmacology, 2009, 2, 373-379.	1.3	3

#	ARTICLE	IF	CITATIONS
55	Spontaneous Hemoptysis in a Patient With COVID-19. Chest, 2021, 160, e39-e44.	0.4	3
56	Voriconazole toxicity masquerading as septic shock. Leukemia and Lymphoma, 2015, 56, 1170-1171.	0.6	2
57	Immune globulin use at a multihospital medical center. American Journal of Health-System Pharmacy, 1994, 51, 801-805.	0.5	1
58	Infectious Complications of Cryoablation and Microwave Ablation in Metastatic Solid Tumors. Infection Control and Hospital Epidemiology, 2018, 39, 723-726.	1.0	1
59	Hyperpigmented Macule on the Palm and Diminished Sensation. JAMA - Journal of the American Medical Association, 2018, 320, 2029.	3.8	1
60	Striking absence of "œusual suspects" during the winter of the coronavirus disease 2019 (COVID-19) pandemic 2020"2021. Infection Control and Hospital Epidemiology, 2021, , 1-2.	1.0	1
61	Prophylaxis Versus a Preemptive Approach for Invasive Aspergillosis. Current Fungal Infection Reports, 2010, 4, 30-37.	0.9	0
62	Successful therapy with Ledipasvir/Sofosbuvir for hepatitis C reactivation in a hematopoietic stem cell transplant recipient. Leukemia and Lymphoma, 2016, 57, 2693-2695.	0.6	0
63	Pre-exposure Prophylaxis in HIV: Is it Time to Act Now?. Journal of the Association of Physicians of India, The, 2020, 68, 89.	0.0	0